Prudential Financial Inc. Has $3.51 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Prudential Financial Inc. increased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 33.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,077 shares of the company's stock after purchasing an additional 20,880 shares during the period. Prudential Financial Inc. owned 0.13% of Vera Therapeutics worth $3,513,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics in the 4th quarter worth $34,000. KBC Group NV grew its holdings in Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after acquiring an additional 1,387 shares during the period. Moors & Cabot Inc. bought a new stake in Vera Therapeutics in the fourth quarter worth about $220,000. E Fund Management Co. Ltd. lifted its holdings in Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after acquiring an additional 1,130 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Vera Therapeutics by 109.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company's stock valued at $416,000 after purchasing an additional 4,914 shares in the last quarter. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA traded down $1.43 during trading on Friday, reaching $21.31. The stock had a trading volume of 1,278,591 shares, compared to its average volume of 771,536. Vera Therapeutics, Inc. has a 52 week low of $20.27 and a 52 week high of $51.61. The stock has a fifty day simple moving average of $29.82 and a two-hundred day simple moving average of $38.32. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.36 billion, a price-to-earnings ratio of -8.16 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. As a group, analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on the stock. Wolfe Research started coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 target price for the company. JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price on the stock. Finally, Guggenheim upped their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $64.67.

Insider Activity

In related news, CEO Marshall Fordyce sold 17,500 shares of the company's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the sale, the chief executive officer now owns 143,603 shares of the company's stock, valued at $5,993,989.22. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 21.70% of the stock is currently owned by company insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.